STAT+: CytoDyn’s wild weekend of data-mining study results ends in failure for its Covid treatment
Results from a late-stage clinical trial released late Friday by the drug maker CytoDyn showed…
Category: biotechnology
STAT+: What to look for in Lilly’s eagerly awaited Alzheimer’s data
Earlier this year, amid the increasingly bruising debate over Biogen’s controversial treatment for Alzheimer’s disease,…
STAT+: Amgen spends $1.9 billion on Five Prime, eyeing an expansion in Asia
Amgen said Thursday it will purchase Five Prime Therapeutics for $1.9 billion to obtain a…
STAT+: Kronos Bio speeds development of genetically targeted leukemia drug with unique trial design
Kronos Bio said Thursday that it had reached an agreement with the Food and Drug…
STAT+: Eli Lilly’s experimental diabetes drug reduced weight and blood sugar in clinical trial
Eli Lilly said Thursday that a study showed its experimental diabetes drug, tirzepatide, reduced patients’…
STAT+: Ovid sells off its lead drug to double down on neuro research
Ovid Therapeutics, months removed from a crushing clinical trial disappointment, said Wednesday that it is…
STAT+: A surprise FDA advisory panel imperils Fibrogen’s experimental anemia pill
Fibrogen was expecting the Food and Drug Administration to complete a review of its experimental…
Sarepta wins new drug approval for patients with Duchenne muscular dystrophy, its third marketed treatment
The Food and Drug Administration on Thursday approved a new medicine from Sarepta Therapeutics that…
STAT+: CytoDyn has data on its highly touted experimental Covid treatment. Investors and patients don’t
CytoDyn CEO Nader Pourhassan has been uncharacteristically quiet this week about a completed clinical trial…
STAT+: With genome-editing companies’ stock booming, Beam Therapeutics seizes its moment
Beam Therapeutics, a company focused on genome editing, is in a strange situation. The firm’s…
STAT+: OpenBiome to wind down stool bank operations
OpenBiome, the nation’s first public stool bank, will soon end its program for collecting, screening,…
STAT+: STAT+ Conversations: A conversation with a leading biotech venture capitalist
Editors Note: A livestream of the conversation will be embedded below at 1 p.m. ET….
STAT+: Brainstorm’s cell therapy for ALS lacks convincing clinical data for FDA submission, agency concludes
The Food and Drug Administration told Brainstorm Therapeutics that rejiggered data from a negative clinical…
.jpg)
Listen: Gene therapy’s safety scare, biotech’s brashest VCs, & the FDA’s uncertain future
How safe is gene therapy? Is there anything “unique” about venture capital? And who’s going…
Virtual Event: Facing the crisis of drug-resistant germs
Editor’s note: A livestream of this event will be posted below at 1 p.m. ET. …
STAT+: Cancer cases place Bluebird Bio’s gene therapy business at a crossroads, and might drag the entire field along
Bluebird Bio’s disclosure Tuesday that two additional patients being treated with its gene therapy for…
Bluebird suspends studies of sickle cell gene therapy following cancer diagnoses in two more treated patients
Bluebird Bio said Tuesday that it has suspended clinical trials involving its gene therapy for…
STAT+: Moncef Slaoui, departing Warp Speed, raises $250 million to test his R&D philosophy in a new company
Moncef Slaoui, who headed the Operation Warp Speed vaccine-development effort under the Trump administration, is…
STAT+: At Flagship Pioneering, the brazen venture capital firm that bankrolled Moderna, there’s a tolerance for failure but not for weakness
Not long ago, the name Flagship Pioneering was as likely to elicit an eye roll…
STAT+: Experts encouraged by Denali’s early results in study of Hunter syndrome drug
A preliminary study of a medicine developed by Denali Therapeutics to treat Hunter syndrome, a…
STAT+: Amicus drug for Pompe disease falls short in key clinical trial, but company will push for approval
Amicus Therapeutics said Thursday that its drug for patients with Pompe disease, a rare genetic…
STAT+: Investing in Pacific Biosciences, SoftBank pays a 540% premium to offer price for entire company
SoftBank, the Japanese tech conglomerate famous for paying questionable sums to invest in startups, has…
STAT+: Gilead’s Galapagos deal disintegrates, a black mark for CEO O’Day
The $5 billion deal that Gilead CEO Daniel O’Day presented as his signature move shortly…
STAT+: In mid-stage study, KalVista pill halts swelling attacks caused by rare, genetic disease
KalVista Pharmaceuticals said Tuesday that its oral, on-demand treatment for the swelling “attacks” commonly experienced…
STAT+: Q&A: James ‘Jim’ Mullen on Editas, why he took the job as CEO, and his vision for the future
On Monday, Editas Medicines announced that veteran biopharma executive James “Jim” Mullen was expanding his…
STAT+: Wife of CytoDyn’s chairman sold $2.6 million in company stock ahead of Covid-19 drug study results
The wife of CytoDyn’s chairman sold $2.6 million in company stock before CytoDyn is expected…
Merck’s Kenneth Frazier, biopharma’s irreplaceable voice, to step down as CEO
Kenneth Frazier is stepping down as the CEO of Merck, leaving a giant hole in…
STAT+: Who will Vertex buy? How much will it spend? Deal questions dominate its earnings call
Who (or what) is Vertex Pharmaceuticals going to buy? The question — asked many different…
.jpg)
STAT+: The FDA delayed its decision on Biogen’s Alzheimer’s drug. Now what?
The Food and Drug Administration’s decision to take three extra months to review Biogen’s controversial…
STAT+: FDA delays approval decision for Biogen’s Alzheimer’s treatment
The Food and Drug Administration is delaying its decision on Biogen’s closely watched Alzheimer’s drug…
STAT+: ‘A milestone in oncology’: Amgen’s KRAS-blocking drug proves effective for lung cancer patients in clinical trial
A drug from Amgen designed to block the cancer protein known as KRAS shrank tumors…
STAT+: ARCH raises $1.85 billion fund, planning to back more big companies
ARCH Venture Partners, the venture capital firm known for helping to arrange huge financings for…
Opinion: The Biden-Harris FDA should make friends with independent researchers
Support for open science — accessible, collaborative, and radically transparent research done outside of traditional…
STAT+: Aurinia secures FDA drug approval for autoimmune kidney disease, with label offering stronger patent protection
Aurinia Pharmaceuticals won approval from the Food and Drug Administration on Friday evening to market…
Covid-19 vaccine supply is running low. Here’s how Biden hopes to fix that
WASHINGTON — The Biden administration is willing to consider almost anything to boost the nation’s…
STAT+: Biotech’s presence on new social media app Clubhouse is growing
For years, Twitter has been biotech’s social media app of choice. But the industry appears…
STAT+: After Moderna’s medical miracle, some investors step back
Moderna performed a miracle last year: The Cambridge biotech company, which hadn’t put a product…
Small biotech launches human trials of a potential ‘backstop’ for Covid-19 vaccines
A small biotechnology firm said that it will start human testing of an experimental Covid-19…
STAT+: Aurinia in ‘show-me phase’ as FDA nears approval decision on autoimmune kidney disease drug
Next week, the Food and Drug Administration is expected to approve a new medicine from…
Virtual Event: STAT@JPM: Facing 2021
Editor’s note: A livestream of the event will be embedded below at 1 p.m. ET….
STAT+: Sana Biotechnology, filing for IPO, aims for astronomical valuation
After years of rumors, Sana Biotechnology is positioning itself to file for an initial public…
STAT+: After repeated FDA rejections, key investor writes down stake in former diabetes unicorn Intarcia Therapeutics
Intarcia Therapeutics, a one-time biotech unicorn that has been unable to secure approval for a…
STAT+: With durable monkey data, Verve selects its first CRISPR base editing treatment for human trials
Verve Therapeutics said Tuesday its one-time treatment that uses the “base editing” form of CRISPR…
STAT+: Gilead’s remdesivir sales are surging, but investors aren’t impressed
A lot more Covid-19 patients in the U.S. are being treated with Gilead Sciences’ remdesivir…
STAT+: Lilly’s preliminary Alzheimer’s data adds $4 billion to Biogen’s value
Biogen added more than $4 billion in market value on Monday after a rival Alzheimer’s…
STAT+: Vertex Pharma taking more aggressive M&A stance, flush with cash from cystic fibrosis drugs
Vertex Pharmaceuticals is looking to acquire “mid- and late-stage assets” to bolster its current research…
STAT+: Bluebird Bio intends to split into two companies, but for now, its troubles are also divided
Splitting Bluebird Bio into two publicly traded companies — one focused on cell therapies for…
STAT+: Tempus unveils prototype cube that talks back to oncologists
Tempus, a Chicago-based health technology company, wants oncologists to talk to the cube. The cube,…
STAT+: Company dedicated to cutting drug prices raises lots of money, releases few details
EQRx, a startup that made waves last year when it announced a plan to develop…
STAT+: Eli Lilly says drug slowed Alzheimer’s decline in preliminary study
An experimental medicine appeared to slow the decline of patients with the early symptoms of…